Baudax Bio Secures Permanent J-Code (J1738) for ANJESO® from Centers for Medicare and Medicaid Services

Aug 06, 2020 7:00am EDT

Baudax Bio Announces Presentation of New Phase IIIb ANJESO® Data at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Meeting

Jul 30, 2020 4:05pm EDT

Baudax Bio Secures Pharmacy Supplier Agreement with Vizient Inc. for ANJESO®

Jul 20, 2020 7:00am EDT

Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 03, 2020 3:25pm EDT

Baudax Bio Announces Full Commercial Launch of ANJESO™ and Receipt of Unique C-Code and Pass-Through Payment Status Effective July 1, 2020

Jun 15, 2020 7:00am EDT

Baudax Bio Secures $50 Million Credit Facility

Jun 01, 2020 7:00am EDT

Baudax Bio Reports First Quarter 2020 Financial Results

May 08, 2020 7:00am EDT

Baudax Bio Announces Presentation of New Phase IIIb ANJESO™ Data at Digestive Disease Week 2020

May 05, 2020 7:00am EDT

Baudax Bio Announces Change in Location of its 2020 Annual Meeting of Shareholders to its Corporate Headquarters

May 01, 2020 4:05pm EDT

Baudax Bio Announces Presentation of New Phase IIIb ANJESO™ Data at the 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting

Apr 23, 2020 7:00am EDT